IDSA GUIDELINE – Diagnosis and Treatment of Leishmaniasis – Clinical Practice Guidelines by the IDSA and ASTMH CID
Clinical Infectious Diseases December 15, 2016 V.63 N.12 P.1539-1557
Naomi Aronson1, Barbara L. Herwaldt2, Michael Libman3, Richard Pearson4, Rogelio Lopez-Velez5, Peter Weina6, Edgar M. Carvalho7, Moshe Ephros8, Selma Jeronimo9, and Alan Magill10
1Uniformed Services University of the Health Sciences, Bethesda, Maryland
2Centers for Disease Control and Prevention, Atlanta, Georgia
3McGill University Health Centre, Montreal, Quebec, Canada
4University of Virginia School of Medicine, Charlottesville
5Ramón y Cajal University Hospital, Madrid, Spain
6Walter Reed National Military Medical Center, Bethesda, Maryland
7Gonçalo Moniz Research Center, FIOCRUZ, Salvador, Bahia, Brazil
8Carmel Medical Center, Haifa, Israel
9Federal University of Rio Grande do Norte, Natal, Brazil
10Bill and Melinda Gates Foundation, Seattle, Washington
It is important to realize that leishmaniasis guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. The IDSA and ASTMH consider adherence to these guidelines to be voluntary, with the ultimate determinations regarding their application to be made by the physician in the light of each patient’s individual circumstances.
Entry filed under: Antiparasitarios, Biología Molecular, CONSENSOS, FIEBRE en el POST-VIAJE, GUIDELINES, Infecciones emergentes, Infecciones en piel y tej blandos, Infecciones parasitarias, Medicina del viajero, Metodos diagnosticos, REVIEWS, Sepsis, Zoonosis.